SequelSEC

BioScience Health Innovations, Inc. BHIC

Services-Computer Processing & Data Preparation · CIK 0001784440 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.04M
Fiscal year ended 2026-06-30
Operating income
-$217.88K
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$43.92MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$3.86Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income68.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue7.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity29.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Computer Processing & Data Preparation filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth208.3%87th
Operating margin12.6%84th
Gross margin57.0%41th

BioScience Health Innovations, Inc. (BHIC) reported revenue of $1.04M and net income of -$185.75K for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from BioScience Health Innovations, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Computer Processing & Data Preparation.

Income

BioScience Health Innovations, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$1.04M$750.95K$1.57M$1.13M$1.76M$1.23M$610.22K$572.97K$384.17K$277.60K
Cost of revenue$376.88K$265.35K$1.00M$433.20K$682.98K$330.92K$271.21K$148.23K$73.79K$42.84K
Gross profit$659.48K$485.60K$571.86K$698.23K$1.07M$896.14K$339.01K$424.74K$310.38K$234.76K
Operating income-$217.88K-$229.91K-$156.67K-$8.78K$457.70K$426.80K$9.96K$56.20K$74.22K-$53.38K
Net income-$185.75K-$229.91K-$233.63K-$8.78K$457.70K$426.80K$9.96K$56.20K$74.22K-$53.38K
Research & development$70.58K$49.72K-$28.83K$19.59K$9.24K$37.54K-$3.90K$26.01K$2.99K$805
Weighted-average diluted sharesshares 11.68Mshares 11.38MUnavailableshares 10.98Mshares 11.40Mshares 44.34MUnavailableshares 10.89Mshares 42.02Mshares 41.39M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense-$32.13KUnavailableUnavailableUnavailable$0Unavailable$0$0UnavailableUnavailable
Diluted EPS$-0.02$-0.02Unavailable$0.00$0.04$0.01Unavailable$0.01$0.00$0.00
Selling, general & administrativeUnavailable$625.81K$656.20K$576.66K$540.07K$433.56K$300.17K$345.29K$222.65K$278.29K
General & administrative$804.14KUnavailableUnavailableUnavailable$540.07KUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

BioScience Health Innovations, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$712.38K$1.15M$661.92K$1.14M$1.30M$1.03M$662.52K$333.22K$143.92K$92.94K
Total assets$2.14M$2.33M$1.71M$2.07M$2.06M$1.39M$873.79K$415.83K$213.59K$154.80K
Current assets$1.99M$2.19M$1.56M$1.99M$1.99M$1.34M$847.75K$408.79K$213.59K$154.80K
Total liabilities$301.21K$645.75K$229.85K$356.14K$337.63K$132.92K$38.55K$45.55K$24.51K$39.94K
Current liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total equity incl. NCI$1.83M$1.68M$1.48M$1.71M$1.72M$1.26M$835.24K$370.28K$189.08K$114.86K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$797.18K$874.34K$336.35K$757.50K$248.52K$215.70K$58.32K$42.22K$40.60K$40.43K
Accounts receivable$396.90K$78.28K$399.26K$63.21K$390.01K$93.45K$100.28K$31.91K$27.63K$21.43K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$9.72K$6.79K$6.27K$10.16K$16.64K$16.42K$8.23K$8.45K$7.01K$4.23K

Cash flow

BioScience Health Innovations, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$541.87K-$552.11K-$100.70K-$340.44K$285.01K$328.31K-$50.30K$52.23K$69.30K-$48.04K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$26.96K$0-$10.79K$0-$16.06K-$30.00K-$19.00K-$7.04K$0$0
Financing cash flow$136.20K$1.04M-$366.02K$180.46K$2.12K$67.52K$398.60K$144.10K-$18.31K$121.74K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

BioScience Health Innovations, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin63.6%64.7%36.4%61.7%61.1%73.0%55.6%74.1%80.8%84.6%
Operating margin-21.0%-30.6%-10.0%-0.8%26.0%34.8%1.6%9.8%19.3%-19.2%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratioUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Revenue YoY growth-41.0%-38.8%157.7%97.5%357.5%342.0%101.0%198.2%453.0%758.5%
Net margin-17.9%UnavailableUnavailable-0.8%26.0%Unavailable1.6%9.8%UnavailableUnavailable
R&D / revenue6.8%6.6%Unavailable1.7%0.5%Unavailable-0.6%4.5%0.8%0.3%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BHIC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-10-27View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.